Harbin Gloria Pharmaceuticals Hits Day High with 6.98% Surge

Harbin Gloria Pharmaceuticals Co., Ltd. has experienced a significant uptick in its stock performance, gaining 6.98% on March 27, 2026. The stock reached an intraday high of CNY 3.38, reflecting a strong day of trading for the mid-cap company in the Pharmaceuticals & Biotechnology sector. Over the past year, Harbin Gloria has demonstrated impressive resilience, with a return of 33.73%, outperforming the China Shanghai Composite, which recorded a 16.01% increase during the same period. The company's year-to-date performance stands at 9.77%, contrasting with the composite's decline of 1.39%. Despite some challenges in long-term growth, as indicated by a net sales decline of 7.25% over the last five years, the company has shown positive momentum in recent quarters, with a notable 47.42% increase in net profit. Additionally, the operating cash flow reached a high of CNY 455.92 million, and the return on capital employed (ROCE) improved to 14.47%. Overall, Harbin Gloria Pharmaceuticals continues to navigate a complex market landscape while maintaining a competitive edge in its sector.